TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Enteral Zinc to Improve Growth in Infants at Risk for Bronchopulmonary Dysplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 23 0/7 to 29 6/7 weeks GA~2. Birth weight 501 to 1000g, inclusive~3. 14 to 28 days of life, inclusive~4. 14 day BPD risk score ≥ 50% for death or moderate-severe BPD, calculated using the algorithm on the Neonatal Research Network website (https://neonatal.rti.org/index.cfm?fuseaction=BPDCalculator.start).-~Exclusion Criteria:~1. Major congenital and/or chromosomal anomalies~2. Inability to reach 80ml/kg/day enteral feeds by 28 days of life

- Gender: ALL
- Minimum Age: 14 Days
- Maximum Age: 28 Days
- Healthy Volunteers: f

Study Arms:
- Zinc plus standard of care (Type: ACTIVE_COMPARATOR): Infants will receive daily doses of zinc at 2mg/kg from enrollment through 35 6/7 weeks corrected gestational age.
- Standard of care only (Type: PLACEBO_COMPARATOR): Infants will not receive any doses of zinc through 35 6/7 weeks corrected gestational age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Fasting TG ≥ 200 mg/dL (2.26 mmol/L) and \< 500 mg/dL (5.65 mmol/L) at Visit 1 (Screening/Enrollment Visit) or Visit 1.1 (Retest)~2. HDL-C ≤ 40 mg/dL (1.03 mmol/L) at Visit 1 (Screening/Enrollment Visit) or Visit 1.1 (Retest)~3. Type 2 diabetes of longer than 12 weeks duration documented in medical records, for example: local laboratory evidence through medical record review of elevated HbA1c (≥ 6.5% \[48 mmol/mol\]), elevated plasma glucose (fasting ≥ 126 mg/dL \[7.0 mmol/L\], 2-hour ≥ 200 mg/dL \[11.1 mmol/L\] during oral glucose tolerance testing, or random value ≥ 200 mg/dL with classic symptoms, or currently taking medication for treatment of diabetes; AND either~   1. Age ≥ 50 years if male or ≥ 55 years if female (primary prevention cohort); OR~  2. Age ≥ 18 years and established systemic atherosclerosis (secondary prevention cohort), defined as any 1 of the following:~      * i. Prior MI or ischemic (non-hemorrhagic) stroke~     * ii. Coronary angiographic lesion of ≥ 60% stenosis in a major epicardial vessel or ≥ 50% left main stenosis~     * iii. Asymptomatic carotid disease with ≥ 70% carotid artery stenosis~     * iv. Symptomatic carotid disease with ≥ 50% carotid artery stenosis~     * v. Symptomatic lower extremity PAD (ie, intermittent claudication, rest pain, lower extremity ischemic ulceration, or major amputation with either ankle-brachial index ≤ 0.9 or other diagnostic testing \[eg, toe-brachial index, angiogram, or other imaging study\])~     * vi. Prior arterial revascularization procedure (including coronary, carotid, or peripheral angioplasty/stenting, bypass, or atherectomy/endarterectomy)~Exclusion Criteria:~1. Current or planned use of fibrates or agents with PPAR-α agonist activity (eg, saroglitazar) within 6 weeks (42 days) of Visit 1 (Screening/Enrollment Visit). Note: PPAR-γ agonists (eg, glizatones such as pioglitazone and rosiglitazone) are allowed~2. Known sensitivity to PPAR-α agonists or tablet excipients~3. Initiation of, or change in, current TG-lowering therapy within 12 weeks of Visit 1 (if applicable). Note: TG-lowering therapy is defined as niacin \> 100 mg/day or dietary supplements or prescription omega-3 fatty acids \> 1 g/day~4. Type 1 diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Type: EXPERIMENTAL): K-877 (pemafibrate) tablet twice daily.
- Control Group (Type: PLACEBO_COMPARATOR): Matching K-877 placebo tablet twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Analgesia for 2nd Trimester Termination of Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* interruption of pregnancy between 12 and 23 6/7 weeks~Exclusion Criteria:~* documented allergy to fentanyl or bupivacaine~* coagulopathy~* drug or narcotic abuse~* contraindication to neuraxial analgesia~* inability to comply with IVPCA or PCEA~* inability to complete the QoR-40 questionnaire~* TOP due to maternal problems

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Epidural (PCEA) (Type: ACTIVE_COMPARATOR): bupivacaine, fentanyl
- IV PCA (Type: ACTIVE_COMPARATOR): Intravenous fentanyl patient controlled analgesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Behavioural Problems in Huntington Disease : Analysis and Enhancement of Caregiver and Patient Experience

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* For patients:~  * Patients with Huntington Disease declared~ * Huntington Disease diagnosed with abnormal number of CAG repeats: 38 \< nucleotide expansion (CAG)~ * Total Functional Capacity ≥ 7~ * Patients living with a caregiver~ * Aged 18 years and above~ * Subject gave its written consent~* For caregivers :~  * No risk of caregiver having Huntington disease~ * Aged 18 years and above~ * Subject gave its written consent~Exclusion Criteria:~* For patients:~  * Patient who do not live with a caregiver~ * No national health insurance affiliation~ * Being under guardianship~* For caregivers :~  * Caregiver at risk for Huntington Disease~ * No national health insurance affiliation~ * Being under guardianship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Patients (Type: OTHER): None
- Caregivers (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Ischemic Conditioning (Delay Phenomenon) in Colorectal Surgery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Are at least 18 years of age, male or female~* Are scheduled for a non-emergent, resection of your colon~* Are able to give written informed consent to indicate an understanding of the study procedures.~Exclusion Criteria~* Will be undergoing an emergency procedure or has a diagnosis of bowel complication(s) such as bowel obstruction, constriction, inflammation, infection, or have inflammatory bowel disease.~* Are currently participating in another clinical trial which may affect this study's outcomes.~* Have been taking regular steroid medication.~* Have a negative reaction to general anesthesia.~* Have severe arterial occlusive disease (disease of the blood vessels affecting blood flow to your legs).~* Have an abdominal aortic aneurysm (dilation of the large artery in your abdomen).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Catheterization (Type: EXPERIMENTAL): Patients receive angioembolization prior to surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Assessment of Oxidative Stress Markers and the Development of Atrial Fibrillation After Cardiac Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Sinus rhythm at the time of enrollment as documented by ECG, telemetry, or Holter monitoring~* Scheduled for an open heart surgery~* Able to provide informed consent~Exclusion Criteria:~* Systemic inflammatory diseases (e.g., collagen vascular diseases, infections)~* Malignant neoplasms~* Hyperthyroidism~* Uncontrolled hypertension (blood pressure \> 180/100 at rest) on medications~* An illness that might result in death within 1 year~* Implanted devices for designed for active management of atrial arrhythmias by pacing or defibrillation~* Current illicit drug use~* Current ethanol abuse~* Presence of paroxysmal, persistent, or permanent atrial fibrillation at the time of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Post operative atrial fibrillation (Type: None): To evaluate the ability of oxidative stress markers to predict postoperative atrial fibrillation in subjects undergoing cardiac surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate Short-term Efficacy of Palliative Methylphenidate in Asthenia in Advanced Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced cancer; including metastatic, locally advanced or relapsed not amenable for curative treatment.~* Mini.mental status examination results within normal limits.~* Informed consent.~* Estimated life expectancy of at least one month.~* Hemoglobin \>= 9 g/dl.~* Asthenia \>= 5 (0-10; numeric verbal scale).~Exclusion Criteria:~* History of psychosis.~* Structured suicidal ideation.~* Severe anxiety.~* Severe renal, hepatic or cardiac (arrythmia, hypertension, ischemic heart disease) failure.~* Simultaneous treatment with drugs that may interact with methylphenidate as: coumarinics, anticonvulsivants (phenobarbital, phenitoin, primidone), phenylbutazone, inhibitors of mono-amine-oxidase, guanethidine.~* History of glaucoma.~* Hyperthyroidism.~* History of hypersensibility to methylphenidate.~* Clinical suspicion of: infection, hypercalcemia, hypothyroidism or renal failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- methylphenidate (Type: EXPERIMENTAL): methylphenidate (pill) p.o. 15 to 25 mg daily for six days
- placebo (Type: PLACEBO_COMPARATOR): the same number of pills (p.o.) than methylphenidate for six days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of DSCT With IB-IVUS and Angiography in the Assessment of Coronary Artery Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males or non-pregnant females~* \> / = 18 years of age~* Scheduled for coronary angiography~Exclusion Criteria:~* Acute ST-elevation myocardial infarction within last 72 hours~* Current congestive heart failure~* Current cardiogenic shock~* Unstable clinical condition~* Known cardiomyopathy (EF \< 30%)~* Creatinine \>1.5 mg/dL~* Definite allergy to iodinated contrast media~* Current participation in an investigational drug or device research study~* HR \> 65 and contraindications to the administration of beta blockers~Exclusion criteria assessed during catheterization procedure~* PCI of native coronary vessel not performed~* Left main stenosis \> 50%~* Any vessel contraindicated for IVUS imaging~* Any lesion contraindicated for IVUS imaging~* Inability to pass IVUS catheter~* PCI of bifurcation lesion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): All patients will receive integrated backscatter IVUS and dual source CT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically documented unresectable Stage III NSCLC that has not progressed following definitive platinum based CRT or extensive disease (Stage IV) SCLC~* ECOG performance status of 0 or 1~* For participants with SCLC: At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 TL at baseline~* Absence of EGFR mutation or ALK rearrangement prior to screening~Exclusion Criteria:~* History of allogeneic organ transplantation~* Autoimmune or inflammatory disorders, diverticulitis, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome~* Uncontrolled intercurrent illness~* History of another primary malignancy~* History of active primary immunodeficiency~* Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)~* Brain metastases or spinal cord compression~* Persistent toxicities (CTCAE Grade \>2) caused by previous anticancer therapy, excluding alopecia~* Receipt of live attenuated vaccine within 30 days prior to the first dose of IP

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Patients with NSCLC (Type: EXPERIMENTAL): Patients with Non-Small Cell Lung Cancer
- Patients with SCLC (Type: EXPERIMENTAL): Patients with Small Cell Lung Cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males or females 18 years of age or older~* Diagnosis of tendonitis or bursitis of the shoulder, elbow or knee~* Meet pain entry criteria~* Willing to discontinue use of any pain medication not provided by study~Exclusion Criteria:~* Have tendonitis or bursitis secondary to a systemic inflammatory disease, calcification or requiring surgery~* Have received corticosteroids in the 30 days preceding screening~* Have a history or physical examination finding that is incompatible with safe participation in the study~* Have a history or physical examination finding that is incompatible with study product use~* Are taking medications or other substances contraindicated due to the nature of the study medication or the potential for drug interactions.~* Are taking medications that may significantly affect renal function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Double Dose of Vaginal Progesterone to no Treatment for Prevention of Preterm Birth in Twins and Short Cervix

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Twin gestation~* Certain dating (documented first trimester ultrasound, or a reliable menstrual date confirmed by an ultrasound performed before 20 weeks of gestation)~* Age \> 18 years~* Gestational age 16-26~* Cervical length\<25 mm~* Intact membranes~* Informed consent~Exclusion Criteria:~* Major malformation or chromosomal abnormality to at least one fetus~* Higher order pregnancy~* Mocochorional-monoamniotic twin~* Death of one fetus~* Cervical dilatation \>3 cm~* Chronic medical conditions that would interfere with study participation or evaluation of the treatment (e.g. seizures, psychiatric disorders, uncontrolled chronic hypertension, congestive heart failure, chronic renal failure, uncontrolled diabetes mellitus with end-organ dysfunction, active thrombophlebitis or a thromboembolic disorder, history of hormone-associated thrombophlebitis or thromboembolic disorders, active liver dysfunction or disease, known or suspected malignancy of the breast or genital organs)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Treatment with 400 mg Micronized progesterone (Utrogestan) daily up to 6 weeks of geastation
- No treatment (Type: NO_INTERVENTION): No treatment. Regular follow up

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥18 years old~* Life expectancy of at least 2 months~* Off previous cancer therapy for at least 14 days, or 5 half-lives for noncytotoxic agents prior to first study treatment administration~* Patients must have a calculated creatinine clearance \>60 mL/min~* Acceptable hematologic, renal and liver functions and coagulation status parameters~Exclusion Criteria:~* Patients with GVHD requiring systemic immunosuppressive therapy~* Uncontrolled leptomeningeal disease, auto-immune hemolytic anemia and uncontrolled and clinical significant disease related metabolic disorder~* Clinically significant intravascular coagulation~* Treatment with other investigational drugs within 14 days prior to first study treatment administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Escalation and Expansion (Type: EXPERIMENTAL): APTO-253 will be given in ascending doses in patients with relapsed or refractory AML or high risk MDS (escalation cohort), until the maximum tolerated dose or recommended dose is reached. Followed by up to 30 patients enrolled in the expansion cohort at the recommended dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: BReath Hold TecHniquEs for Radiotherapy of Esophageal Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven esophageal cancer of the mid or distal esophagus~* Scheduled for external-beam photon radiotherapy with curative intention.~* WHO 0-2.~* Age \>= 18 years~* Written informed consent.~Exclusion Criteria:~* Serious respiratory distress~* Contra-indication for fiducial marker placement~* Noncompliance with any of the inclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABC DIBH (Type: ACTIVE_COMPARATOR): Active Breathing Controlled (ABC) technique for deep breath inspiration hold (DIBH)
- VC DIBH (Type: EXPERIMENTAL): Voluntary Coached (VC) technique for deep breath inspiration hold (DIBH)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of an advanced, malignant, solid tumor(s) with all standard treatment options having been exhausted or declined.~* Eastern Cooperative Group (ECOG) performance status is 0-2 at Screening.~* Measurable disease per RECIST v1.1 by radiographic techniques~* Acceptable liver function, serum creatinine and hematological status~* Female subjects of childbearing potential, and male subjects with partners of childbearing potential, must agree to use medically acceptable methods of contraception beginning on Study Day 1 and continuing until at least four weeks after administration of the subject's final dose of RRx-001.~* Subjects with brain metastases are eligible~Exclusion Criteria:~* Concurrent anticancer therapy; however, radiotherapy is allowed~* Any history of hypersensitivity to irinotecan~* Cholangitis that required treatment or intervention within 4 weeks of study enrollment~* Bilirubin \> 2.0 mg/dL~* Serious medical or psychiatric illness likely to interfere with participation in this clinical study~* If female, subject is pregnant and/or breastfeeding.~* UGT1A1\*28 homozygote or heterozygote~* BMI \>35

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RRx-001 + Irinotecan (Type: EXPERIMENTAL): Cohorts of participants with an advanced, malignant, solid tumor(s) will receive weekly doses of RRx-001 for 3 weeks, switching at week 4 to every-other-week treatments of RRx-001 with irinotecan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues